Cargando…
Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity
Vectors based on adeno-associated viruses (AAV) have shown considerable promise in both preclinical models and increasingly in clinical trials. However, one formidable challenge is pre-existing immunity due to widespread exposure to numerous AAV variants and serotypes within the human population, wh...
Autores principales: | Bartel, Melissa, Schaffer, David, Büning, Hildegard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Research Foundation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3207363/ https://www.ncbi.nlm.nih.gov/pubmed/22065962 http://dx.doi.org/10.3389/fmicb.2011.00204 |
Ejemplares similares
-
Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors
por: Büning, Hildegard, et al.
Publicado: (2019) -
Immunogenicity of Novel AAV Capsids for Retinal Gene Therapy
por: Gehrke, Miranda, et al.
Publicado: (2022) -
Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction
por: Fitzpatrick, Zachary, et al.
Publicado: (2018) -
Modifying immune responses to adeno-associated virus vectors by capsid engineering
por: Bentler, Martin, et al.
Publicado: (2023) -
Evading the AAV Immune Response in Mucopolysaccharidoses
por: Piechnik, Matthew, et al.
Publicado: (2020)